The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pulmonary Arterial Hypertension (PAH) Market Research Report 2024
Synopsis
The global Pulmonary Arterial Hypertension (PAH) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Pulmonary Arterial Hypertension (PAH) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Pulmonary Arterial Hypertension (PAH) include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Arterial Hypertension (PAH).
Report Scope
The Pulmonary Arterial Hypertension (PAH) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Arterial Hypertension (PAH) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Arterial Hypertension (PAH) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
Segment by Type
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Pulmonary Arterial Hypertension (PAH) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pulmonary Arterial Hypertension (PAH) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Pulmonary Arterial Hypertension (PAH) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Pulmonary Arterial Hypertension (PAH) include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Arterial Hypertension (PAH).
Report Scope
The Pulmonary Arterial Hypertension (PAH) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Arterial Hypertension (PAH) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Arterial Hypertension (PAH) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
Segment by Type
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Prostacyclin and Prostacyclin Analogs
1.2.3 SGC Stimulators
1.2.4 ERA
1.2.5 PDE-5
1.3 Market by Application
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2019-2030)
2.2 Pulmonary Arterial Hypertension (PAH) Growth Trends by Region
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2019-2024)
2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2025-2030)
2.3 Pulmonary Arterial Hypertension (PAH) Market Dynamics
2.3.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
2.3.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
2.3.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
2.3.4 Pulmonary Arterial Hypertension (PAH) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue
3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2019-2024)
3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2019-2024)
3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
3.4 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
3.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2023
3.5 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
3.6 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
3.7 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2019-2024)
4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2025-2030)
5 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2019-2024)
5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2019-2030)
6.2 North America Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024)
6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2019-2030)
7.2 Europe Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024)
7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2019-2030)
8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2019-2024)
8.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2019-2030)
9.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024)
9.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2019-2030)
10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2019-2024)
10.4 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Actelion
11.1.1 Actelion Company Detail
11.1.2 Actelion Business Overview
11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
11.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.1.5 Actelion Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
11.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.2.5 Gilead Sciences Recent Development
11.3 United Therapeutics
11.3.1 United Therapeutics Company Detail
11.3.2 United Therapeutics Business Overview
11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
11.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.3.5 United Therapeutics Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
11.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
11.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Bayer
11.6.1 Bayer Company Detail
11.6.2 Bayer Business Overview
11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
11.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.6.5 Bayer Recent Development
11.7 Arena
11.7.1 Arena Company Detail
11.7.2 Arena Business Overview
11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
11.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2019-2024)
11.7.5 Arena Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
